SCHEMBL13627882

SCHEMBL13627882

O=C1/C(=N\O)c2ccccc2N1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
UCHL3 P15374 2/20 0.47
UCHL1 P09936 2/20 0.47
ALDH1A1 P00352 4/20 0.46
MAPT P10636 3/20 0.46
TSHR P16473 3/20 0.46
BCHE P06276 2/20 0.46
CES1 P23141 2/20 0.46
CES2 O00748 1/20 0.46
MAPK1 P28482 1/20 0.46
P2RX7 Q99572 3/20 0.44
ALDH2 P05091 1/20 0.44
ALDH3A1 P30838 1/20 0.44
HSD17B10 Q99714 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627881 0.83 CES1 (0.67) CA12CA1CA2CA9LMNA
SCHEMBL30774282 0.83 CES1 (0.67) CA12CA1CA2CA9LMNA
SCHEMBL18974316 0.83 CES1 (0.67) CA12CA1CA2CA9LMNA
SCHEMBL13627885 0.82 ALDH1A1 (0.54) CA12CA2CA9LMNAPOLB
SCHEMBL13627884 0.81 MAPT (0.52) CA12CA1CA2CA9LMNA
SCHEMBL12856311 0.79 ALDH1A1 (0.47) CA12CA1CA2CA9LMNA
SCHEMBL13627878 0.79 ALDH1A1 (0.70) CA12CA1CA2CA9LMNA
SCHEMBL7611054 0.78 ALDH1A1 (0.66) CA12CA1CA2CA9LMNA
SCHEMBL7611051 0.78 ALDH1A1 (0.66) CA12CA1CA2CA9LMNA
SCHEMBL13627934 0.78 UCHL3 (0.50) CA12CA1CA2CA9UCHL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CA12 4791/4885CA1 3628/4885CA2 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.